• Something wrong with this record ?

Radical cystectomy for bladder cancer in solid organ transplant recipients

E. Tonin, L. Bianchi, A. Mottaran, S. Brönimann, F. Berndl, S. Biolcati, M. Droghetti, F. Chessa, B. Pradere, E. Comperat, R. Schiavina, E. Brunocilla, SF. Shariat, D. D'Andrea

. 2025 ; 77 (2) : 202-208. [pub] -

Language English Country Italy

Document type Journal Article, Multicenter Study

Persistent link   https://www.medvik.cz/link/bmc25016202

BACKGROUND: Solid organ transplant recipients (SOTRs) face higher cancer risk because of immunosuppressive therapy used to prevent organ rejection. We hypothesized that SOTRs treated with radical cystectomy (RC) and pelvic lymph-node dissection (PLND) for bladder cancer (UBC) might have worse survival outcomes compared to non-SOTRs. This study aims to assess survival outcomes of SOTRs treated with RC and PLND for UBC compared to non-SOTRs. METHODS: A retrospective analysis of 645 patients treated with RC and PLND for UBC, originating from our multicenter cooperation program (2002-2022), stratified in two groups according to previous solid organ transplantation. Co-primary endpoints were OS and CSS, assessed using mixed-effects Cox-analysis. Secondary endpoints included postoperative complications, readmission-rates, operation time, estimated blood loss and length of stay. RESULTS: Of the 361 patients analyzed (median follow-up: 17 months), 23 were SOTRs. SOTRs exhibited lower 12-month (70% vs. 80%) and 24-month (36% vs. 68%) OS-rates compared to non-SOTRs (P=0.011). Corresponding CSS-rates were also lower for SOTRs at 12 (81% vs. 85%) and 24 months (55% vs. 76%) (P=0.016). Multivariable Cox-regression identified a prior solid organ transplant (OR:5.2; P=0.002), higher pathologic-stage (OR:3.8; P=0.03 for pT2, OR:3.6; P=0.04 for pT3, OR:4.5; P=0.03 for pT4), and administration of "any systemic treatment" (OR:0.3; P=0.001) as OS predictors. For CSS, predictors were a prior solid organ transplant (OR:3.0; P=0.03), higher pathologic-stage (OR:9.8; P=0.04 for pT3, OR:13; P=0.02 for pT4), and administration of "any systemic treatment" (OR:0.4; P=0.03). CONCLUSIONS: Solid organ transplant recipients undergoing RC and PLND for urinary UBC have worse survival outcomes compared to non-SOTRs. Our findings may impact patient counseling, follow-up, and planning future clinical trials.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc25016202
003      
CZ-PrNML
005      
20250731091610.0
007      
ta
008      
250708s2025 it f 000 0|eng||
009      
AR
024    7_
$a 10.23736/S2724-6051.25.06130-0 $2 doi
035    __
$a (PubMed)40298345
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a it
100    1_
$a Tonin, Elena $u Division of Urology, IRCCS University Hospital, Bologna, Italy $u Department of Urology, Santa Maria delle Croci Hospital, Ravenna, Italy
245    10
$a Radical cystectomy for bladder cancer in solid organ transplant recipients / $c E. Tonin, L. Bianchi, A. Mottaran, S. Brönimann, F. Berndl, S. Biolcati, M. Droghetti, F. Chessa, B. Pradere, E. Comperat, R. Schiavina, E. Brunocilla, SF. Shariat, D. D'Andrea
520    9_
$a BACKGROUND: Solid organ transplant recipients (SOTRs) face higher cancer risk because of immunosuppressive therapy used to prevent organ rejection. We hypothesized that SOTRs treated with radical cystectomy (RC) and pelvic lymph-node dissection (PLND) for bladder cancer (UBC) might have worse survival outcomes compared to non-SOTRs. This study aims to assess survival outcomes of SOTRs treated with RC and PLND for UBC compared to non-SOTRs. METHODS: A retrospective analysis of 645 patients treated with RC and PLND for UBC, originating from our multicenter cooperation program (2002-2022), stratified in two groups according to previous solid organ transplantation. Co-primary endpoints were OS and CSS, assessed using mixed-effects Cox-analysis. Secondary endpoints included postoperative complications, readmission-rates, operation time, estimated blood loss and length of stay. RESULTS: Of the 361 patients analyzed (median follow-up: 17 months), 23 were SOTRs. SOTRs exhibited lower 12-month (70% vs. 80%) and 24-month (36% vs. 68%) OS-rates compared to non-SOTRs (P=0.011). Corresponding CSS-rates were also lower for SOTRs at 12 (81% vs. 85%) and 24 months (55% vs. 76%) (P=0.016). Multivariable Cox-regression identified a prior solid organ transplant (OR:5.2; P=0.002), higher pathologic-stage (OR:3.8; P=0.03 for pT2, OR:3.6; P=0.04 for pT3, OR:4.5; P=0.03 for pT4), and administration of "any systemic treatment" (OR:0.3; P=0.001) as OS predictors. For CSS, predictors were a prior solid organ transplant (OR:3.0; P=0.03), higher pathologic-stage (OR:9.8; P=0.04 for pT3, OR:13; P=0.02 for pT4), and administration of "any systemic treatment" (OR:0.4; P=0.03). CONCLUSIONS: Solid organ transplant recipients undergoing RC and PLND for urinary UBC have worse survival outcomes compared to non-SOTRs. Our findings may impact patient counseling, follow-up, and planning future clinical trials.
650    _2
$a lidé $7 D006801
650    12
$a nádory močového měchýře $x chirurgie $x mortalita $x patologie $7 D001749
650    12
$a cystektomie $x metody $7 D015653
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a retrospektivní studie $7 D012189
650    _2
$a lidé středního věku $7 D008875
650    12
$a transplantace orgánů $7 D016377
650    _2
$a senioři $7 D000368
650    _2
$a lymfadenektomie $7 D008197
650    _2
$a pooperační komplikace $x epidemiologie $7 D011183
650    _2
$a příjemce transplantátu $7 D066027
650    _2
$a míra přežití $7 D015996
655    _2
$a časopisecké články $7 D016428
655    _2
$a multicentrická studie $7 D016448
700    1_
$a Bianchi, Lorenzo $u Division of Urology, IRCCS University Hospital, Bologna, Italy
700    1_
$a Mottaran, Angelo $u Division of Urology, IRCCS University Hospital, Bologna, Italy
700    1_
$a Brönimann, Stephan $u Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria
700    1_
$a Berndl, Florian $u Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria
700    1_
$a Biolcati, Stefano $u Division of Urology, IRCCS University Hospital, Bologna, Italy
700    1_
$a Droghetti, Matteo $u Division of Urology, IRCCS University Hospital, Bologna, Italy
700    1_
$a Chessa, Francesco $u Division of Urology, IRCCS University Hospital, Bologna, Italy
700    1_
$a Pradere, Benjamin $u Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria $u Department of Urology, Croix Du Sud Hospital, Quint-Fonsegrives, France
700    1_
$a Comperat, Eva $u Department of Pathology, Medical University of Vienna, Vienna, Austria
700    1_
$a Schiavina, Riccardo $u Division of Urology, IRCCS University Hospital, Bologna, Italy
700    1_
$a Brunocilla, Eugenio $u Division of Urology, IRCCS University Hospital, Bologna, Italy
700    1_
$a Shariat, Shahrokh F $u Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria $u Department of Urology, University of Texas Southwestern, Dallas, TX, USA $u Department of Urology, Second Faculty of Medicine, Charles University, Prague, Czech Republic $u Hourani Center for Applied Scientific Research, AI-Ahliyya Amman University, Amman, Jordan $u Karl Landsteiner Institute of Urology and Andrology, Vienna, Austria $u Research Center for Evidence Medicine, Urology Department, Tabriz University of Medical Science, Tabriz, Iran
700    1_
$a D'Andrea, David $u Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria - david.dandrea@meduniwien.ac.at
773    0_
$w MED00208300 $t Minerva urology and nephrology $x 2724-6442 $g Roč. 77, č. 2 (2025), s. 202-208
856    41
$u https://pubmed.ncbi.nlm.nih.gov/40298345 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20250708 $b ABA008
991    __
$a 20250731091605 $b ABA008
999    __
$a ok $b bmc $g 2366798 $s 1253327
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2025 $b 77 $c 2 $d 202-208 $e - $i 2724-6442 $m Minerva urology and nephrology $n Minerva Urol Nephrol $x MED00208300
LZP    __
$a Pubmed-20250708

Find record

Citation metrics

Archiving options